Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels

Abstract Background and Aims Regorafenib has demonstrated its survival benefit for unresectable hepatocellular carcinoma (uHCC) patients in a phase III clinical trial. We aimed to assess the efficacy and tolerability of regorafenib and the predictors of treatment outcomes in Taiwanese patients. Meth...

Full description

Bibliographic Details
Main Authors: Po‐Yao Hsu, Tzu‐Sheng Cheng, Shih‐Chang Chuang, Wen‐Tsan Chang, Po‐Cheng Liang, Cheng‐Ting Hsu, Yu‐Ju Wei, Tyng‐Yuan Jang, Ming‐Lun Yeh, Ching‐I Huang, Yi‐Hung Lin, Chih‐Wen Wang, Ming‐Yen Hsieh, Nai‐Jen Hou, Meng‐Hsuan Hsieh, Yi‐Shan Tsai, Yu‐Min Ko, Ching‐Chih Lin, Kuan‐Yu Chen, Chia‐Yen Dai, Zu‐Yau Lin, Shinn‐Cherng Chen, Jee‐Fu Huang, Wan‐Long Chuang, Chung‐Feng Huang, Ming‐Lung Yu
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Cancer Medicine
Subjects:
efficacy
hepatocellular carcinoma
regorafenib
sorafenib
Online Access:https://doi.org/10.1002/cam4.4430

Internet

https://doi.org/10.1002/cam4.4430

Similar Items